Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides

International Journal of Colorectal Disease

Volumn 17, Issue 4, 2002, Pages 223-232

  Spiik, Ann Kristin ^a   Ridderstad, Anna ^a   Axelsson, Lars Göran ^b   Midtvedt, Tore ^b,c   Björk, Lars ^d   Pettersson, Sven ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Biovitrum AB   (Sweden)

Author keywords

Antisense oligonucleotides; CD14; Inflammatory bowel disease; Lamina propria mononuclear cells; Nuclear factor B

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD14 ANTIGEN; CYTOKINE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR PROTEIN; SYNAPTOTAGMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CECUM; CELL COUNT; CELL LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMETRY; DNA BINDING; EUTHANASIA; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; IMMUNOFLUORESCENCE TEST; INTESTINE CELL; LAMINA PROPRIA; LASER; LYMPHOCYTIC COLITIS; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE DRUG DOSE;

ANIMALS; ANTIGENS, CD14; COLITIS; DEXTRAN SULFATE; FEMALE; HUMANS; LYMPHOCYTES; MALE; MICE; NF-KAPPA B; OLIGONUCLEOTIDES, ANTISENSE; TIME FACTORS;

EID: 0036935106     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-001-0366-3     Document Type: Article

References (52)

1. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al (1996) Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogates established experimental colitis in mice. Nat Med 2:998-1004
2. Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071
3. Bonn D (1998) Tackling the real culprits in Crohn's disease. Lancet 351:1710
4. Marok R, Winyard PG, Coumbe A, et al (1996) Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 39:583-591
5. Wahl C, Liptay S, Adler G, et al (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101:1163-1174
6. Miagkov AV, Kovalenko CE, Brown JR, et al (1998) NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 95:13859-13864
7. Reinecker HC, Steffen T, Witthoeft I, et al (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 93:174-181
8. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141-179
9. Shakhov AN, Collart MA, Vassalli P, et al (1990) Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171:35-47
10. Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327-2334
11. Neurath MF, Fuss I, Kelsall BL, et al (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281-1290
12. Podolsky DK (1995) Inflammatory bowel disease. N Engl J Med 325:928-935
13. Rogler G, Brand K, Vogel S, et al (1998) Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115:357-369
14. Schreiber S, Nikolaus S, Hampe J (1998) Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 42:477-484
15. Grilli M, Chiu JJ, Lenardo MJ (1993) NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol 143:1-62
16. Maniatis T (1997) Catalysis by a multiprotein IkappaB kinase complex. Science 278:818-819
17. Sha WC, Liou HC, Tuomanen EI, Baltimore D (1995) Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80:321-330
18. Cato AC, Wade E (1996) Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 18:371-378
19. Sartor RB (1992) Animal models of intestinal inflammation. Relevance to inflammatory bowel disease. Inflammatory bowel disease. Elsevier, Science, New York, pp 337-353
20. Axelsson L-G, Landström E, Bylund-Fellenius A-C (1992) Effects of sulphasalazine on survival of athymic mice with dextran sulphate (DSS) induced colitis. Gut 33 [Suppl 39]
21. Bylund-Fellenius A-C, Landström E, Axelsson L-G, et al (1994) Experimental colitis induced by dextran sulphate in normal and germfree mice. Microb Ecol Health Dis 7:207-215
22. Greenfield SM, Hamblin ZS, Shahkoor JP, et al (1993) Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine. Gut 34:252-256
23. Murthy S, Cooper H, Shim H, et al (1993) Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 36:1722-1734
24. Buell MG, Berin MC (1994) Neutrophil-independence of the initiation of colonic injury. Comparison of results from three models of experimental colitis in the rat. Dig Dis Sci 39:2575-2588
25. Weldon MJ, Maxwell JD (1994) Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for gene therapy? Gut 35:867-871
26. Kamentsky LA, Kamentsky LD (1991) Microscope-based multiparameter laser scanning cytometer yielding data comparable to flow cytometry data. Cytometry 12:381-387
27. Deptala A, Bedner E, Gorczyca W, et al (1998) Activation of nuclear factor kappa B (NF-kappaB) assayed by laser scanning cytometry (LSC). Cytometry 33:376-382
28. Schesser K, Spiik A-K, Dukuzumuremyi JM, et al (1998) The yopJ locus is required for Yersinia-mediated inhibition of NF-kappaB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity. Mol Microbiol 28:1067-1079
29. Schumann RR, Leong SR, Flaggs PW, et al (1990) Structure and function of lipopolysaccharide binding protein. Science 249:1429-1431
30. Ulevitch RJ, Tobias PS (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13:437-457
31. Barnes PJ, Adcock I (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 14:436-441
32. Auphan N, DiDonato JA, Rosette C, et al (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290
33. Wang CY, Mayo MW, Baldwin AS Jr (1996) TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274:784-787
34. Heck S, Bender K, Kullmann M, et al (1997) I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J 16:4698-4707
35. Karin M (1998) New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93:487-490
36. Axelsson LG, Landström E, Bylund-Fellenius AC (1998) Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment Pharmacol Ther 12:925-934
37. Ricote M, Li AC, Willson TM, et al (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82
38. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
39. Su CG, Wen X, Bailey W, et al (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383-389
40. Barroso I, Urnell VE, Crowley M, et al (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
41. Sarraf P, Mueller WM, Smith HM, et al (1999) Loss-of-function mutations in PPAR gamma associated with human colon. Mol Cell Biol 3:799-804
42. Stein CA, Cheng YC (1993) Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261:1004-1012
43. Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333-335
44. Crooke ST (1992) Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329-376
45. Stec WJ, Zon G, Egan W, et al (1984) Automated solid-phase synthesis, separation and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J Am Chem Soc 106:6077-6079
46. Stein CA, Tonkinson JL, Yakubov L (1991) Phosphorothioate oligodeoxy-nucleotides - anti-sense inhibitors of gene expression? Pharmacol Ther 52:365-384
47. Wright SD, Ramos RA, Tobias PS, et al (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433
48. Grimm MC, Pavli P, Van de Pol E, et al (1995) Evidence for a CD14+ population of monocytes in inflammatory bowel disease mucosa - implications for pathogenesis. Clin Exp Immunol 100:291-297
49. Kopp EB, Medzhitov R (1999) The Toll-receptor family and control of innate immunity. Curr Opin Immunol 11:13-18
50. Poltorak A, He X, Smirnova I, et al (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088
51. Meijer LK, Schesser K, Wolf-Watz H, et al (2000) The bacterial protein YopJ abrogates multiple signal transduction pathways that converge on the transcription factor CREB. Cell Microbiol 2:1-9
52. Rembacken BJ, Snelling AM, Hawkey PM, et al (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635-639